Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs.
The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | -2.75 Decreased by -1.43 K% | -1.99 Decreased by -38.19% |
| Aug 13, 24 | -1.74 Decreased by -255.10% | -2.31 Increased by +24.68% |
| May 13, 24 | -2.84 Decreased by -300.00% | -2.08 Decreased by -36.54% |
| Mar 5, 24 | -2.97 Decreased by -241.38% | -3.18 Increased by +6.60% |
| Nov 7, 23 | -0.18 Increased by +81.25% | -0.35 Increased by +48.57% |
| Aug 9, 23 | -0.49 Increased by +62.88% | -0.66 Increased by +25.76% |
| May 11, 23 | -0.71 Increased by +52.98% | -0.79 Increased by +10.13% |
| Feb 7, 23 | -0.87 Increased by +33.08% | -0.78 Decreased by -11.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 302.00 K Decreased by -35.47% | -51.91 M Decreased by -110.74% | Decreased by -17.19 K% Decreased by -226.58% |
| Jun 30, 24 | 357.00 K Decreased by -54.29% | -32.68 M Increased by +4.77% | Decreased by -9.15 K% Decreased by -108.34% |
| Mar 31, 24 | 431.00 K Decreased by -36.90% | -39.55 M Decreased by -7.43% | Decreased by -9.18 K% Decreased by -70.24% |
| Dec 31, 23 | 515.00 K Increased by +N/A% | -26.88 M Increased by +34.27% | Decreased by -5.22 K% Decreased by N/A% |
| Sep 30, 23 | 468.00 K Increased by +N/A% | -24.63 M Increased by +43.50% | Decreased by -5.26 K% Decreased by N/A% |
| Jun 30, 23 | 781.00 K Increased by +N/A% | -34.31 M Increased by +42.81% | Decreased by -4.39 K% Decreased by N/A% |
| Mar 31, 23 | 683.00 K Increased by +N/A% | -36.82 M Increased by +46.32% | Decreased by -5.39 K% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -40.89 M Increased by +30.20% | Decreased by N/A% Decreased by N/A% |